Our article on heart development is out in Nature!

Glad we could be part of this international project on heart development! Congratulations to Gonzalo del Monte Nieto and Richard Harvey!

Abstract: In vertebrate hearts, the ventricular trabecular myocardium develops as a sponge-like network of cardiomyocytes that is critical for contraction and conduction, ventricular septation, papillary muscle formation and wall thickening through the process of compaction. Defective trabeculation leads to embryonic lethality or non-compaction cardiomyopathy (NCC). There are divergent views on when and how trabeculation is initiated in different species. In zebrafish, trabecular cardiomyocytes extrude from compact myocardium, whereas in chicks, chamber wall thickening occurs before overt trabeculation. In mice, the onset of trabeculation has not been described, but is proposed to begin at embryonic day 9.0, when cardiomyocytes form radially oriented ribs. Endocardium–myocardium communication is essential for trabeculation, and numerous signalling pathways have been identified, including Notch and Neuregulin (NRG). Late disruption of the Notch pathway causes NCC5. Whereas it has been shown that mutations in the extracellular matrix (ECM) genes Has2 and Vcan prevent the formation of trabeculae in mice and the matrix metalloprotease ADAMTS1 promotes trabecular termination, the pathways involved in ECM dynamics and the molecular regulation of trabeculation during its early phases remain unexplored. Here we present a model of trabeculation in mice that integrates dynamic endocardial and myocardial cell behaviours and ECM remodelling, and reveal new epistatic relationships between the involved signalling pathways. NOTCH1 signalling promotes ECM degradation during the formation of endocardial projections that are critical for individualization of trabecular units, whereas NRG1 promotes myocardial ECM synthesis, which is necessary for trabecular rearrangement and growth. These systems interconnect through NRG1 control of Vegfa, but act antagonistically to establish trabecular architecture. These insights enabled the prediction of persistent ECM and cardiomyocyte growth in a mouse NCC model, providing new insights into the pathophysiology of congenital heart disease.

Go to the full article: Del Monte-Nieto G, Ramialison M, Adam AAS, Wu B, Aharonov A, D’Uva G, Bourke LM, Pitulescu ME, Chen H, de la Pompa JL, Shou W, Adams RH, Harten SK, Tzahor E, Zhou B and Harvey RP. Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation. Nature, 2018

Fellowship opportunity in our lab

We are recruiting a research fellow at MultiMedica ONLUS Foundation (Milan). The contract is for 1 year, starting from June 2018, and potentially renewable for a total of three years.
The project is funded by Cariplo Foundation and the research will be conducted in our laboratory, which forms a bridge between the fields of cancer, cardiotoxicity of anticancer therapies and cardiac regeneration.

The selected research fellow will develop a project on the cardiotoxicity of anti-cancer therapies. Cardio-toxicity is a common side effect of chemotherapy and targeted anti-cancer therapies, strongly impacting on the quality of life and the overall survival, regardless of the oncological prognosis. The goal is to develop strategies for reducing the cardiotoxic side effects of current anti-cancer therapies, while simultaneously improving their efficacy. By employing both breast cancer cells and primary mouse cardiomyocytes cultures in vitro, the research activities will be focused on the role of specific growth factors and receptors on cell differentiation status, and the impact on tumour growth and cardiotoxic side effects. In vivo analysis on mouse models will also be conducted.

Applicants requirements: Applicants must have a molecular-, cell- and biochemistry backgrounds, such as a Master Degree in Biotechnology, Biology or related field. Candidates must have at least one year of experience in a research laboratory. Familiarity with standard molecular biology techniques (Real Time PCR, Western Blot, Immunofluorescence analysis…), as well as the expertise in cardiac and/or tumour biology, are required. Passion for science as well as a positive attitude towards solving problems is required in order to pursue technically challenging and intellectually stimulating projects in the lab.

Other criteria: PhD Degree is not required, but is positively evaluated. Expertise in procedures for the induction of cardiac damage (by cardiotoxic drugs or myocardial infarction) as well as in the analysis of microarray o RNA-seq datasets is a plus factor for the selection process.

How to apply: Applicants should send their CV by email with subject line “Research fellowships at Fondazione MultiMedica ONLUS” to Dr. Gabriele D’Uva (gabriele.duva@multimedica.it). One or more letters of recommendation are welcome, although not strictly required. Interviews will be conducted for selected candidates until the position is filled.

Previous publications relevant to the project:
• D’Uva G et al., ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nature Cell Biology, 2015
• D’Uva G and Tzahor E, The key roles of ERBB2 in cardiac regeneration. Cell Cycle. 2015
• Yutzey KE. Regenerative biology: Neuregulin 1 makes heart muscle. Nature, 2015 (News & Views on our article)
• D’Uva G and Lauriola M, Towards the emerging cross-talk: ERBB family and steroid hormones. Seminars in Cell and Developmental Biology, 2016

Our article on heart regeneration is out in Stem Cell Reports!

Happy to have collaborated to this international project on mammalian heart regeneration! Congratulations to Diana Nascimento and her team!

Abstract: So far, opposing outcomes have been reported following neonatal apex resection in mice, questioning the validity of this injury model to investigate regenerative mechanisms. We performed a systematic evaluation, up to 180 days after surgery, of the pathophysiological events activated upon apex resection. In response to cardiac injury, we observed increased cardiomyocyte proliferation in remote and apex regions, neovascularization, and local fibrosis. In adulthood, resected hearts remain consistently shorter and display permanent fibrotic tissue deposition in the center of the resection plane, indicating limited apex regrowth. However, thickening of the left ventricle wall, explained by an upsurge in cardiomyocyte proliferation during the initial response to injury, compensated cardiomyocyte loss and supported normal systolic function. Thus, apex resection triggers both regenerative and reparative mechanisms, endorsing this injury model for studies aimed at promoting cardiomyocyte proliferation and/or downplaying fibrosis.

Go to the full article: Sampaio-Pinto V, Rodrigues S, Laúndos T, Silva E, Nóvoa F, Silva A, Cerqueira R, Resende T, Pianca N, Leite-Moreira A, D’Uva G, Thorsteinsdóttir S, Pinto-do-Ó P, Nascimento DS. Neonatal Apex Resection Triggers Cardiomyocyte Proliferation, Neovascularization and Functional Recovery Despite Local Fibrosis. Stem Cell Report, 2018

D’Uva lab receives Cariplo grant award on cancer and cardiotoxicity

We have just received very good news: we won the research grant “Cariplo – Young Researchers“.
This grant will allow us, in parallel to ongoing studies in the field of cardiac regeneration following a heart attack, to expand our research on cancer and the emerging problem of cardiotoxicity of anticancer therapies.
Cardiotoxicity, i.e. toxic effects on heart function, is responsible for a poor quality of life and reduced survival of cancer patients, regardless of the oncologic prognosis. The aim of our research is to develop innovative strategies to limit these side effects while increasing the efficacy of anti-cancer therapies targeting HER2 (a well-known oncogene also known as ERBB2) in breast cancer patients.
The project is in collaboration with the University of Bologna and Biomedical Research Foundation / University of Turin.
These funds will also give us the opportunity to recruit another researcher into my team. Soon we will post the details.
Happy 2018 to everyone!